<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

Press Releases

Our latest announcements

Biodesix Anticipates Strong Preliminary Fourth Quarter 2020 Revenue (unaudited)

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company expects to report record fourth quarter 2020 preliminary unaudited revenue in a range of $25 million to $27 million.

Purdue partners with Colorado company to offer rapid testing for students ahead of spring 2021 semester

Purdue University is partnering with a Colorado company led by a Purdue alum to offer rapid antigen COVID-19 testing for undergraduate, graduate and professional students taking classes on the West Lafayette campus who will be living off campus (not in the residence halls or in Fraternity, Sorority and Cooperative Life housing) during the spring 2021 semester.

Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer

Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer.

Biodesix Initiates Biomarker Study to Affirm Nodify XL2® Test’s Importance in Clinical Decision Making

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, is proud to announce the launch and active recruitment of a firstin-class biomarker study aligned with the recommendations from the official 2018 American Thoracic Society (ATS) policy statement on the early detection of lung cancer.

Biodesix Study Shows Proprietary Device Collects, Separates, and Transports Blood at Ambient Temperature

Biodesix Study Shows Proprietary Device Collects, Separates, and Transports Blood at Ambient Temperature. Findings Suggest Blood Collection Device Simplifies Specimen Collection and Transport While Maintaining Accuracy of Diagnostic Test Results

Biodesix Announces Third Quarter 2020 Results and Provides Corporate Update

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the third quarter ended September 30, 2020 and provided a corporate update.

Biodesix Publishes Extended Analyses of the Nodify XL2® Lung Nodule Test

Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the company’s Nodify XL2® lung nodule test.

Biodesix Announces Pricing of Initial Public Offering

Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share.

Biodesix Announces Data from Three Studies on Lung Nodule Diagnosis and Management to be Shared at CHEST Annual Meeting 2020

Data presented at the American College of Chest Physicians (CHEST) annual meeting, demonstrate the value of the Nodify Lung™ testing strategy and confirm previously reported performance of the Nodify XL2® and Nodify CDT™ tests.

Big Ten Conference Partners with Biodesix, Inc. and Quidel Corporation

The Big Ten Conference has entered into strategic partnerships with Biodesix, Inc., a leading diagnostic company with a focus on lung disease, and Quidel Corporation, the manufacturer of the FDA-authorized SOFIA 2 SARS rapid antigen test.

First 1 2 3 4 5 6 7 8 9 Last